New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.

Merck completes $10B acquisition of Verona Pharma, adding Ohtuvayre — the first new inhaled COPD therapy in over 20 years.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio November 20 marks World COPD Day 2024, a ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

The development could help scientists develop patient-specific treatments and one day offer a lab-grown lung transplant ...

Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional ...

The global pharmaceutical company GSK announced the launch of “Trelegy Ellipta” following the approval of the Egyptian Drug Authority. Trelegy represents a new breakthrough in the treatment of chronic ...

Anemia is a common and clinically significant comorbidity in chronic obstructive pulmonary disease (COPD), contributing to worsened respiratory function, reduced exercise capacity and overall quality ...

A recent study published in the journal of Respiratory Medicine revealed that children with higher body mass index (BMI) ...